SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

"Shina Inu is a decentralized meme token on the Ethereum blockchain. Its mission is to give back to the crypto community, give to charity, and win the heart of the greatest token of all time, Shiba Inu!   Shina Token is a very fun meme token project that has sold many rare and beautiful NFTs. NFT sales are used to support the team and provide upcoming features such as exclusive access to events and rewards that will soon be announced."

Shina Inu

Shina Inu is trending as community members highlight its strong chart setup, accumulation patterns, and potential for a breakout. The focus is on bullish technical indicators and growing momentum, with some suggesting it could be the next big community-driven crypto run. Overall, the community sentiment points towards anticipation for a significant upward move.

Ainalyzr is a versatile and engaging platform designed to provide crypto traders with advanced tools and a fun, interactive environment. Powered by the Ainalyzr token, it offers real-time analysis of Solana-based tokens, gamified trading tools, and a space for users to explore market trends and make data-driven decisions. Ainalyzr merges functionality and entertainment, appealing to both seasoned and novice traders.

AInalyzr

AInalyzr ($AINAL.X) is gaining attention as community members anticipate a potential breakout, citing bullish chart patterns and encouraging others to "stack" before it's too late. The crypto is being touted as a hidden gem with "rocket" potential, with many emphasizing the opportunity to get in early. Conversations suggest a strong sense of conviction among those already invested.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is surging, sparking excitement among its community who are eyeing potential gains and referencing a possible DOJE ETF. Discussions revolve around holding strategies, potential price targets, and whether this rally has enough momentum to reach previous highs. Some community members are suggesting that it is on track to reach $1 soon.

Aventus

Aventus ($AVT.X) is trending as community members highlight its low market cap and potential for a breakout, with some comparing it to other trending tokens. Recent company updates on LinkedIn, particularly partnerships and the appchain model, are generating discussion, as are technical analyses suggesting bullish patterns. Some traders are expressing frustration with $AVT.X's inability to hold gains.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Conversations around DJT are currently focused on political division and the recent death of Charlie Kirk, with community members expressing strong opinions and engaging in heated debates. Some users are pointing fingers and assigning blame, while others are calling for unity and an end to political violence. The stock appears to be heavily influenced by broader socio-political narratives.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The crypto "crow with knife" ($CAW.X) is trending, driven by community enthusiasm and its growing presence as a meme coin, particularly within the Cronos ($CRO.X) ecosystem.  Active discussions revolve around its unique branding and potential, with supporters emphasizing its community-driven nature and multichain functionality across $SOL.X, $CRO.X, and $ETH.X.

"What's Updog?" is a Community Led token.

UpDog

UpDog is trending as community members highlight its charitable donations to dog shelters, with many expressing excitement about the project's potential and comparing it to other meme coins. The community is actively discussing the coin's mission and anticipating further gains, viewing it as a 'dog-coin' with a cause. There is also increased interest around 'what is UpDog?'

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as the community rallies around a potential breakout, fueled by bullish chart patterns and significant accumulation by key players. Many are pointing to $AINAL.X as the next big opportunity within the Solana ecosystem, urging others to get in early before a potential surge. The overall sentiment suggests strong momentum and anticipation for further gains in the near future.

Shiba Inu (SHIB) is a meme token which began as a fun currency and has now transformed into a decentralized ecosystem. During the initial launch, 50% of the supply was allocated into Vitalik Buterin's ethereum wallet.   As a result of that, Vitalik proceeded to donate 10% of his SHIB holdings to a COVID-19 relief effort in India and the remaining 40% is burnt forever. That donation was worth about $1 billion at that time, which makes it one of the largest donation ever in the world.  What is the Shiba Inu community working on right now? The Shiba Inu team launched a decentralized exchange called Shibaswap with 2 new tokens, LEASH and BONE. LEASH is a scarce supply token that is used to offer incentives on Shibaswap. BONE is the governance token for holders to vote on proposals on Doggy DAO.

Shiba Inu

Shiba Inu is trending with community members debating its potential for growth and comparing it to other meme coins like DOGE and BONK. Some are optimistic about its future, while others express frustration with its price action and question its utility. Discussions also include the impact of broader market trends and potential developments within the SHIB ecosystem.

Avalanche is a high throughput smart contract blockchain platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is trending as the crypto community anticipates a potential breakout, fueled by mentions of bullish technical formations and anticipation of altcoin season. Community members are actively discussing key resistance levels and potential price targets, with some pointing to fundamental developments like partnerships and real-world asset tokenization as catalysts. Despite some frustration with price action, there's a sense of underlying optimism about AVAX's long-term potential and undervalued status within the Layer 1 landscape.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street Analysts Believe Revolution Medicines (RVMD) Could Rally 90.58%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 90.6% in Revolution Medicines (RVMD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Royalty Pharma Plc. (RPRX) on Tuesday announced a $2 billion funding arrangement with Revolution Medicines (RVMD), aimed at supporting the latter’s plans for global development of its investigational cancer drug Daraxonrasib.As per the <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-enters-2-billion-flexible-funding-agreement">arrangement</a>, Royalty Pharma will provide up to $1.25 billion to Revolution Medicines in exchange for a synthetic royalty on annual worldwide net sales of Daraxonrasib for a term of 15 years and a senior secured loan of up to $750 million.Synthetic royalty financing is a type of funding where a company sells a portion of its future revenue stream in exchange for upfront capital, without relinquishing ownership of the underlying asset.Funds worth $1.25 billion will be awarded in five tranches upon Revolution Medicines hitting certain product development milestones. The first two $250 million tranches, totaling $500 million, are payable prior to the FDA’s approval of Daraxonrasib, and royalty obligations begin only after that.The funds, Royalty Pharma said, will support Revolution Medicines’ plans for global development and commercialization of Daraxonrasib and its pipeline programs for patients with RAS-addicted cancers.Daraxonrasib is an experimental drug in late-stage development for RAS mutant pancreatic cancer and non-small cell lung cancer (NSCLC). RAS is one of the most commonly mutated genes in human cancer, and the drug works by targeting RAS proteins.In the U.S., approximately 56,000 patients are diagnosed with RAS-driven pancreatic cancer annually, while approximately 60,000 patients are diagnosed with RAS-driven NSCLC annually, Royalty Pharma said.Revolution Medicines expects late-stage trial results for Daraxonrasib in pancreatic cancer in 2026.Revolution Medicines CEO Mark A. Goldsmith said that the funding agreement “significantly increases” the financial resources the company can deploy.The company had cash, cash equivalents, and marketable securities of $2.1 billion as of March 31. The company said on Tuesday that it is removing its cash runway end date guidance owing to the new funding agreement.On Stocktwits, retail sentiment around RVMD fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours while message volume increased from ‘low’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:626/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_24_at_9_43_59_AM_png_4b2fb6ec49.webp" alt="RVMD's Sentiment Meter and Message Volume as of 9:40 a.m. ET on June 24, 2025 | Source: Stocktwits" width="626" height="64"><figcaption>RVMD's Sentiment Meter and Message Volume as of 9:40 a.m. ET on June 24, 2025 | Source: Stocktwits</figcaption></figure>As for RPRX, retail sentiment stayed unmoved within ‘bearish’ territory over the past 24 hours while message volume improved from ‘low’ to ‘normal’ levels.<figure class="image"><img style="aspect-ratio:631/66;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_24_at_9_45_20_AM_png_2660096f57.webp" alt="RPRX's Sentiment Meter and Message Volume as of 9:45 a.m. ET on June 24, 2025 | Source: Stocktwits" width="631" height="66"><figcaption>RPRX's Sentiment Meter and Message Volume as of 9:45 a.m. ET on June 24, 2025 | Source: Stocktwits</figcaption></figure> RVMD is trading nearly 2% lower on Tuesday morning.While <a href="https://stocktwits.com/symbol/RVMD">RVMD stock</a> is down by about 10% this year, <a href="https://stocktwits.com/symbol/RPRX">RPRX</a> is up by about 41%.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/verizon-ai-powered-overhaul-of-customer-support-draws-retail-praise/chm49CNRR34">Verizon’s AI-Powered Overhaul Of Customer Support Draws Retail Praise</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Revolution Medicines company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Revolution Medicines To Get Up To $2B For Development Of Cancer Drug From Royalty Pharma

Royalty Pharma will provide up to $1.25 billion to Revolution Medicines in exchange for a synthetic royalty on annual worldwide net sales of Daraxonrasib for a term of 15 years and a senior secured loan of up to $750 million.

Equity

Analysts Offer Insights on Healthcare Companies: Amphastar Pharmaceuticals (AMPH), Revolution Medicines (RVMD) and Personalis (PSNL)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amphastar Pharmaceuticals (AMPH Research Report), Revolution Medicines...

Outperform Rating with Raised Price Target for Revolution Medicines Amid Promising Oncology Trials

Analyst Jonathan Chang from Leerink Partners maintained a Buy rating on Revolution Medicines (RVMD Research Report) and increased the price targe...

Buy Rating Affirmed for Revolution Medicines on Promising RMC-6236 Clinical Data and Market Potential

Leerink Partners analyst Jonathan Chang has maintained their bullish stance on RVMD stock, giving a Buy rating today. Jonathan Chang has given his...

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Revolution Medicines, Inc. (NASDAQ: RVMD)

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Revolution Medicines, Inc. (NASDAQ: RVMD) SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder...

What's Going On With Revolution Medicines Stock?

Revolution Medicines announced the publication of a peer-reviewed research paper in 'Cancer Discovery' detailing the discovery and preclinical to clinical translation for RMC-6236 on Monday. The...

Futures On Edge Ahead Of Critical CPI Report

Futures On Edge Ahead Of Critical CPI Report

 Futures are up small before the March CPI data was expected to show further moderation in price pressures following stronger readings at the...

Revolution Medicines, Inc. (NASDAQ:RVMD) Receives $38.80 Consensus Target Price from Analysts

Revolution Medicines, Inc. (NASDAQ:RVMD - Get Free Report) has been given an average recommendation of "Buy" by the ten brokerages that are presently covering the firm, Marketbeat reports. Ten...

Revolution Medicines to Participate in Upcoming Investor Conferences

REDWOOD CITY, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Current Price	$46.55
Prev Close	$46.24
Open	$46.80
Dividend Yield	0.00%
50-Day Moving Average	$37.75
Beta	1.21
Avg. Volume	2.01M
PE Ratio	-10.26

52-Week High	$62.40
52-Week Low	$29.17
Market Capitalization	$8.64B
EPS (Annual)	-$3.58
Price to Book	4.63
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

RVMD
Revolution Medicines Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest RVMD News

RVMD Revolution Medicines Inc